NCT04750720: ABCOVID

Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection

Completed NA Last updated 30 December 2025

What this trial tests

NA trial testing Sampling by venipuncture (and eventually by nasopharyngeal swab) in Covid19 in 187 participants. Completed in 7 March 2022.

Timeline

27 August 2020

Primary endpoint
7 March 2022

7 March 2022

Quick facts

Lead sponsor	Centre Hospitalier Régional d'Orléans
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	187
Start date	27 August 2020
Primary completion	7 March 2022
Estimated completion	7 March 2022
Sites	1 location across France

Drugs / interventions tested

• Sampling by venipuncture (and eventually by nasopharyngeal swab)

Conditions studied

• Covid19 — all drugs for Covid19 →
• SARS-CoV-2 — all drugs for SARS-CoV-2 →

Sponsor

Centre Hospitalier Régional d'Orléans

Who can join

18 and older, any sex, with Covid19 or SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of the study is to describe the temporal curve of COVID-19 IgG and neutralizing antibodies over 24 months in an identified population of patients who presented with SARS-CoV-2 virus infection. The secondary objectives are to characterize the kinetics of the antibodies according to the severity of the clinical presentation and patient's characteristics and to determine if the anti-SARS-CoV-2 antibodies retain their neutralizing capacity over time. A sub-study aims to describe the kinetic of neutralizing antibodies (in blood and nasal mucosa) after vaccination.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
   Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, et al · · 2023 · cited 161× · PMID 36788246 · DOI 10.1038/s41467-023-36561-6
2. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
   Planas D, Veyer D, Baidaliuk A, Staropoli I, et al · · 2021 · cited 137× · DOI 10.1101/2021.05.26.445838
3. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.
   Planas D, Staropoli I, Porot F, Guivel-Benhassine F, et al · · 2022 · cited 34× · PMID 36228619 · DOI 10.1016/j.medj.2022.09.010
4. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
   Planas D, Saunders N, Maes P, Guivel-Benhassine F, et al · · 2021 · cited 31× · DOI 10.1101/2021.12.14.472630
5. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination.
   Garcia L, Woudenberg T, Rosado J, Dyer AH, et al · · 2022 · cited 25× · PMID 35891471 · DOI 10.3390/v14071491
6. Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021.
   Woudenberg T, Pinaud L, Garcia L, Tondeur L, et al · · 2023 · cited 16× · PMID 37347417 · DOI 10.2807/1560-7917.es.2023.28.25.2200681
7. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
   Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, et al · · 2021 · cited 16× · DOI 10.1101/2021.02.12.430472
8. Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2.
   Clairon Q, Prague M, Planas D, Bruel T, et al · · 2023 · cited 13× · PMID 37549192 · DOI 10.1371/journal.pcbi.1011282